STK1p Based on the Serum Thymidine Kinase 1 as a Tumour Proliferation Marker Detected for Risk Assessment of Pre-carcinoma to Carcinoma Colorectal Progression: A Meta-Analysis | Chapter 02 | New Horizons in Medicine and Medical Research Vol. 8
The goal of this study was to see if serum thymidine kinase 1 concentration (STK1p) could be used to predict the likelihood of progression from colorectal adenoma polyp/dysplasia to colorectal carcinoma using the TK1-IgY-pAb (CRC). The current meta-analysis looked at 25 papers that included patients with CRC (n=2,251), patients with colorectal polyp/dysplasia (n=1,165), and tumor-free controls (n=1,887). From January 1, 2009, to January 31, 2022, the publications were gathered from PubMed, Embase, CENTRAL, CNKI, WanFang, VIP, and SinoMed databases. To calculate the mean difference, articles were analysed using fixed or random effect models. The Newcastle-Ottawa Scale was used to evaluate the quality of the studies that were gathered. The PRISMA statement was followed in the meta-analysis. STK1p was found to be a significant differentiator between tumor-free persons and those with CRC and colorectal adenoma polyp/dysplasia (p0.0001). Meanwhile, STK1p levels in CRC patients reduced...